Treatment of T2N2B Tongue Cancer

Primary Treatment Approach

The standard treatment for T2N2B tongue cancer is surgical resection of the primary tumor with bilateral neck dissection followed by adjuvant postoperative radiotherapy to the tumor bed and bilateral neck regions at 56-60 Gy (or 60-66 Gy if adverse features are present), as recommended by the American College of Radiology 1
Wide local excision (partial glossectomy) with adequate margins (≥5 mm) is the cornerstone of treatment for the primary T2 tongue lesion, according to the National Comprehensive Cancer Network 2

Postoperative radiotherapy is mandatory for T2N2B disease due to the significant nodal involvement, which represents a major risk factor for locoregional recurrence, as stated by the American College of Radiology 1
The standard dose is 56-60 Gy to the tumor bed and bilateral neck regions using once-daily fractionation of 2 Gy per fraction, as recommended by the American Society for Radiation Oncology 1
An escalated dose of 60-66 Gy is recommended if adverse pathologic features are present, including microscopically positive margins, extracapsular nodal extension, or multiple positive nodes, according to the National Comprehensive Cancer Network 1

Concurrent systemic therapy (cisplatin) with radiation should be strongly considered for T2N2B disease given the high-risk features of bilateral nodal involvement, as recommended by the American Society of Clinical Oncology 1
High-dose cisplatin at 100 mg/m² on days 1, 22, and 43 is the preferred regimen when concurrent chemoradiation is used, according to the National Comprehensive Cancer Network 3

Radiation therapy must begin within 6 weeks of surgery to optimize outcomes, as delays beyond this timeframe negatively impact disease control, as stated by the American College of Radiology 1

TSH levels should be monitored every 6-12 months following neck irradiation, as hypothyroidism occurs in 20-25% of patients receiving bilateral neck radiation, according to the American Thyroid Association 1, 2
Regular assessment for xerostomia and other radiation-induced complications is necessary, as recommended by the American Society for Radiation Oncology 1

Failing to perform bilateral neck dissection in N2B disease would leave contralateral disease untreated, as stated by the American Head and Neck Society 1
Underestimating the need for adjuvant radiation in node-positive disease, particularly with bilateral involvement, is a common pitfall, according to the American College of Radiology 1
Delaying radiation therapy start beyond 6 weeks postoperatively can negatively impact disease control, as recommended by the American Society for Radiation Oncology 1
Using unilateral radiation fields when bilateral nodal disease is present is inappropriate, as stated by the American College of Radiology 1
Inadequate surgical margins (<5 mm) would necessitate dose escalation to 60-66 Gy, according to the National Comprehensive Cancer Network 1, 2